Triple pill lowers risk of recurrent stroke by 39%
Researchers report that GMRx2, a single daily pill combining telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg, lowers the risk of recurrent stroke by 39%. The findings from the… read more.
Researchers report that GMRx2, a single daily pill combining telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg, lowers the risk of recurrent stroke by 39%. The findings from the… read more.
People who take gabapentinoids, a medication prescribed increasingly frequently worldwide, particularly for chronic pain, face a much greater risk of drug poisoning if they are also taking another… read more.
Vertex Pharmaceuticals Incorporated announced the FDA has approved expanded use of Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a… read more.
Asundexian, an investigational anti clotting medication, appears to lower the risk of stroke without increasing bleeding in patients who have had a recent stroke or transient ischemic attack… read more.
The antidepressant duloxetine does not appear to prevent chemotherapy-associated nerve damage in colorectal cancer. This finding appeared in the JCO Oncology Advances on March 25, 2026 followed by… read more.
The European Medicines Agency’s key human medicines committee (CHMP) has recommended five medicines for approval at its March 2026 meeting. This brings to 23 the total number of… read more.
Ascendis Pharma announced that Yuviwel (navepegritide; developed as TransCon CNP) was granted orphan drug exclusivity by the FDA and that Yuviwel is now commercially available in the United… read more.
Researchers report that the antidepressant fluvoxamine has significantly reduced long COVID–related fatigue, and that the diabetes drug metformin has no such benefit. “Patients taking fluvoxamine reported steadily improving… read more.
Fake news can be tricky to spot, but spotting fake drugs just got a little easier. Researchers have devised a low-cost way to help distinguish legitimate medications from… read more.
Celltrion Inc. announced that Avtozma (tocilizumab-anoh) subcutaneous (SC) formulation is now available to patients in the United States. With this launch, Celltrion’s Avtozma becomes one of the first tocilizumab… read more.
GLP-1 medications, which are used to treat diabetes and obesity, appear to be associated with reduced hospital care and sickness absence from work for psychiatric reasons, researchers reported… read more.
In terms of clinically relevant bleeding, apixaban is safer than rivaroxaban in the treatment of venous thrombosis, researchers concluded on March 11, 2026 in the NEJM/New England Journal of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.